Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Slides:



Advertisements
Similar presentations
Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.
Advertisements

Applying the New Multiple Sclerosis Guidelines to Clinical Practice
The Nurse View: Management of Pancreatic Cancer
The Nurse View.
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Statin Selection in the Elderly
Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.
The Role of Anticholinergic Therapy in Moderate to Severe Asthma
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Effective Management of Psoriatic Arthritis: Tailoring Treatments
UNDERSTANDING RISK STRATIFICATION IN PAH:
The Nurse View.
Progression After Cancer Immunotherapy in Advanced NSCLC
The Patient Journey to Remission in MDD: A Collaborative Approach
REFLECT: First-Line Lenvatinib vs Sorafenib in HCC Study Design
HIV Management: An Update on the Latest EACS Guidelines
RAI-Refractory Thyroid Cancer: Optimizing Treatment With Multikinase Inhibitors.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Cancer Stem Cell Therapies in Gastrointestinal Cancers
American Heart Association Scientific Sessions
Targeting Thyroid Cancer
Statins and the Elderly Patient
Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
Tailoring Antiplatelet Therapy in PCI
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.
Program Goals Introduction Case 1: A 44-Year-Old Woman.
Best Practices in Metastatic Colorectal Cancer
Treating mRCC After Initial Antiangiogenic Therapy:
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Case Collection in RA: Highlights of an Interactive Workshop
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Improving Appropriate Access to PCSK9 Inhibitors
Program Goals Disclaimer Overview Assessing Disease Activity.
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
New LDL-C Lipid Targets
Immunotherapy for cSCC
Best Practices in the Identification and Management of Alzheimer Agitation.
When Is Biologic Therapy Appropriate for HS?
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Maintenance Therapy in Advanced Ovarian Cancer
When to Start and What to Use
Immune Checkpoint Inhibitors in Lung Cancer
The Road to Quality Improvement in HER2-Positive Breast Cancer
When Is Intrathecal Drug Delivery Appropriate?
Patient-Centered Management in BRAF-Positive Metastatic Melanoma
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Controlling Elevated Blood Pressure
Proteasome Inhibitors and Patients
Program Goal. Program Goal Disclaimer Overview.
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
New Paradigms in M0 CRPC.
When Is Intrathecal Drug Delivery Appropriate?
Prostacyclin Pathway Agents in Action
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
CDK4/6 Inhibitors.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer
Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.
Maximizing Disease-Free Survival in Early-Stage HER2-Positive Breast Cancer.
New Options for the Treatment of Hepatocellular Carcinoma
Identifying TRK Fusions in Head and Neck Cancer
PCSK9 Inhibitors and Real-World Evidence
Presentation transcript:

Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC

Program Goals

Differentiated Thyroid Cancer

Treatment for RAI-R DTC

Guidelines

ATA Guidelines

Case 58-Year-Old Woman With Papillary Thyroid Carcinoma

Follow-Up Questions About the Case

Case (cont)

Case (cont)

Approaches

Case (cont)

Defining RAI-R Disease

Case (cont)

ATA Guidelines on Kinase Inhibitor Therapy

ATA Guidelines Factors Favoring Kinase Inhibitor Therapy

ATA Guidelines Factors Discouraging Kinase Inhibitor Therapy

Case (cont)

First-Line Treatment Options

Sorafenib DECISION Trial

Lenvatinib SELECT Trial

Case (cont)

ATA Guidelines Monitoring

Case Conclusion

Choosing Between Therapies

Second-Line Therapy Options

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.